Holen Sie sich die Stockscreener-App
10.28
0.44%
0.0588
Schlusskurs vom Vortag:
$10.22
Offen:
$10.34
24-Stunden-Volumen:
598.20K
Relative Volume:
0.54
Marktkapitalisierung:
$809.26M
Einnahmen:
$147.19M
Nettoeinkommen (Verlust:
$-274.55M
KGV:
-2.6958
EPS:
-3.8129
Netto-Cashflow:
$-225.38M
1W Leistung:
-3.80%
1M Leistung:
-14.60%
6M Leistung:
-13.30%
1J Leistung:
+143.25%
1-Tages-Spanne:
$10.06
$10.47
1-Wochen-Bereich:
$10.03
$11.77
52-Wochen-Spanne:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
10.27 | 805.32M | 147.19M | -274.55M | -225.38M | -3.8129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital - simplywall.st
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Guggenheim Raises Price Target for Phathom Pharmaceuticals (PHAT) to $25 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Phathom Pharmaceuticals Hits Day High with 10.06% Surge in Stock Price - Markets Mojo
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Phathom stock price target to $25 on revenue beat - Investing.com Canada
Phathom Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-02-27 - Seeking Alpha
Phathom Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Phathom Pharma earnings beat by $0.34, revenue topped estimates - Investing.com Canada
Decoding Phathom Pharmaceuticals Inc (PHAT): A Strategic SWOT In - GuruFocus
Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative - simplywall.st
Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlig - GuruFocus
Stifel reiterates Buy on Phathom stock, keeps $28 price target By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals (PHAT) Stock Analysis: A Look At Its 85.88% Potential Upside - DirectorsTalk Interviews
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 14.3% on Earnings Beat - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals Q4 2025 beats expectations, stock surges - Investing.com Nigeria
Phathom Pharmaceuticals Shares Rise After Q4 Loss Narrows, Revenue Rises - marketscreener.com
Phathom Q4 2025 slides: 217% revenue growth, profitability in sight By Investing.com - Investing.com UK
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.20 - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q4 Revenue $57.6M, vs. FactSet Est of $57.2M - marketscreener.com
PHATHOM PHARMA ($PHAT) Releases Q4 2025 Earnings - Quiver Quantitative
Phathom Pharmaceuticals : Fourth Quarter 2025 Earnings Call Presentation – February 2026 - marketscreener.com
Phathom Pharmaceuticals Q4 revenue slightly beats expectations - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals (PHAT) grows 2025 sales but remains deeply unprofitable - Stock Titan
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Phathom Pharmaceuticals Earnings Review: Q4 Summary - Benzinga
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million - TradingView
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
PHAT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):